Literature DB >> 25321180

Longitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.

Sachin Jain1, Catherine E Oldenburg, Matthew J Mimiaga, Kenneth H Mayer.   

Abstract

Secular trends in nonoccupational postexposure prophylaxis (NPEP) use have not been well characterized. We performed a retrospective longitudinal study of 894 electronic medical records of NPEP users, mostly men who have sex with men, at a Boston community health center who presented between July 1997 and August 2013. NPEP use and condomless sexual exposures increased over time; 19.4% had multiple NPEP courses. Having an HIV-infected partner was associated with increased odds of regimen completion, and 3-drug regimens were associated with decreased odds of completion. Targeted adherence and risk-reduction counseling are warranted for select NPEP users at this center.

Entities:  

Mesh：

Year:  2015        PMID： 25321180      PMCID： PMC4460007          DOI： 10.1097/QAI.0000000000000403

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


  38 in total

1.  HIV medical providers' perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas.

Authors:  Allan E Rodríguez; Amanda D Castel; Carrigan L Parish; Sarah Willis; Daniel J Feaster; Michael Kharfen; Gabriel A Cardenas; Kira Villamizar; Michael Kolber; Liliana Vázquez-Rivera; Lisa R Metsch
Journal:  J Acquir Immune Defic Syndr       Date:  2013-11-01       Impact factor: 3.731

2.  Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.

Authors:  Christian Rabaud; Christine Burty; Michel Grandidier; Bernard Christian; Christian Penalba; Isabelle Béguinot; Henri Jeanmaire; Thierry May
Journal:  Clin Infect Dis       Date:  2004-12-21       Impact factor: 9.079

3.  Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.

Authors:  Dawn K Smith; Lisa A Grohskopf; Roberta J Black; Judith D Auerbach; Fulvia Veronese; Kimberly A Struble; Laura Cheever; Michael Johnson; Lynn A Paxton; Ida M Onorato; Alan E Greenberg
Journal:  MMWR Recomm Rep       Date:  2005-01-21

4.  Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2).

Authors:  R A Otten; D K Smith; D R Adams; J K Pullium; E Jackson; C N Kim; H Jaffe; R Janssen; S Butera; T M Folks
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.

Authors:  Ronald H Gray; Godfrey Kigozi; David Serwadda; Frederick Makumbi; Stephen Watya; Fred Nalugoda; Noah Kiwanuka; Lawrence H Moulton; Mohammad A Chaudhary; Michael Z Chen; Nelson K Sewankambo; Fred Wabwire-Mangen; Melanie C Bacon; Carolyn F M Williams; Pius Opendi; Steven J Reynolds; Oliver Laeyendecker; Thomas C Quinn; Maria J Wawer
Journal:  Lancet       Date:  2007-02-24       Impact factor: 79.321

6.  Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.

Authors:  Robert C Bailey; Stephen Moses; Corette B Parker; Kawango Agot; Ian Maclean; John N Krieger; Carolyn F M Williams; Richard T Campbell; Jeckoniah O Ndinya-Achola
Journal:  Lancet       Date:  2007-02-24       Impact factor: 79.321

7.  Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine.

Authors:  C C Tsai; K E Follis; A Sabo; T W Beck; R F Grant; N Bischofberger; R E Benveniste; R Black
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

8.  A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.

Authors:  D M Cardo; D H Culver; C A Ciesielski; P U Srivastava; R Marcus; D Abiteboul; J Heptonstall; G Ippolito; F Lot; P S McKibben; D M Bell
Journal:  N Engl J Med       Date:  1997-11-20       Impact factor: 91.245

Review 9.  Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV.

Authors:  Ingrid V Bassett; Kenneth A Freedberg; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2004-07-16       Impact factor: 9.079

10.  Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.

Authors:  Bertran Auvert; Dirk Taljaard; Emmanuel Lagarde; Joëlle Sobngwi-Tambekou; Rémi Sitta; Adrian Puren
Journal:  PLoS Med       Date:  2005-10-25       Impact factor: 11.069
View more
  11 in total

1.  The Transition From Postexposure Prophylaxis to Preexposure Prophylaxis: An Emerging Opportunity for Biobehavioral HIV Prevention.

Authors:  Sachin Jain; Douglas S Krakower; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2015-06-01       Impact factor: 9.079

2.  High Levels of Concomitant Behavioral Health Disorders Among Patients Presenting for HIV Non-occupational Post-exposure Prophylaxis at a Boston Community Health Center Between 1997 and 2013.

Authors:  Sachin Jain; Catherine E Oldenburg; Matthew J Mimiaga; Kenneth H Mayer
Journal:  AIDS Behav       Date:  2016-07

3.  Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.

Authors:  Kenneth H Mayer; Daniel Jones; Catherine Oldenburg; Sachin Jain; Marcy Gelman; Shayne Zaslow; Chris Grasso; Matthew J Mimiaga
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-15       Impact factor: 3.731

Review 4.  Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis.

Authors:  Douglas S Krakower; Sachin Jain; Kenneth H Mayer
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

5.  Post-exposure prophylaxis use and recurrent exposure to HIV among men who have sex with men who use crystal methamphetamine.

Authors:  Catherine E Oldenburg; Sachin Jain; Kenneth H Mayer; Matthew J Mimiaga
Journal:  Drug Alcohol Depend       Date:  2014-11-26       Impact factor: 4.492

6.  "It's Like Plan B but for HIV!" Design and Evaluation of a Media Campaign to Drive Demand for PEP.

Authors:  Jeremy Fagan; Victoria Frye; Rose Calixte; Sachin Jain; Lovely Molla; Adeola Lawal; Marcus P Mosley; Emily Greene; Kenneth H Mayer; Barry S Zingman
Journal:  AIDS Behav       Date:  2020-12

7.  Predictors of Standard Follow-Up Completion after Sexual Exposure to HIV: Five-Year Retrospective Analysis in a French HIV-Infection Care Center.

Authors:  Pierre Gantner; Michele Treger; Constance De Miscault; Marie-Laure Batard; Claudine Bernard-Henry; Christine Cheneau; Erik De Mautort; Marialuisa Partisani; Michele Priester; David Rey
Journal:  PLoS One       Date:  2015-12-22       Impact factor: 3.240

8.  A mixed methods study of non-occupational post-exposure prophylaxis at an STI clinic in Singapore: Five-year retrospective analysis and providers' perspectives.

Authors:  Alvin Kuo Jing Teo; Bee Choo Tai; Martin Tze-Wei Chio; Hanh Hao La
Journal:  PLoS One       Date:  2018-08-20       Impact factor: 3.240

9.  Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064.

Authors:  Iris Chen; William Clarke; San-San Ou; Mark A Marzinke; Autumn Breaud; Lynda M Emel; Jing Wang; James P Hughes; Paul Richardson; Danielle F Haley; Jonathan Lucas; Anne Rompalo; Jessica E Justman; Sally L Hodder; Susan H Eshleman
Journal:  PLoS One       Date:  2015-10-07       Impact factor: 3.240

10.  Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.

Authors:  Réjean Thomas; Chrissi Galanakis; Sylvie Vézina; Danièle Longpré; Michel Boissonnault; Emmanuelle Huchet; Louise Charest; Daniel Murphy; Benoît Trottier; Nimâ Machouf
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.